ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.001,60
0,54%
S&P 500
5.127,79
1,26%
Dow Jones
38.675,68
1,18%
Euro vs US Dollar
1,07725
0,00%
Bitcoin
64.418,67
0,81%
Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Lexicon Pharmaceuticals Inc (LXRX)

  7. Lexicon Pharmaceuticals Inc (LXRX) News

LXRX

Lexicon Pharmaceuticals (LXRX)

Lexicon Pharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:LXRX
DatumZeitQuelleÜberschriftSymbolFirma
02/05/202422h05GlobeNewswire Inc.Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/04/202415h00GlobeNewswire Inc.Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon PharmaceuticalsNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/04/202413h00GlobeNewswire Inc.Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024NASDAQ:LXRXLexicon Pharmaceuticals Inc
18/04/202414h00GlobeNewswire Inc.Lexicon Pharmaceuticals to Host 2024 Investor DayNASDAQ:LXRXLexicon Pharmaceuticals Inc
03/04/202414h00GlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
25/03/202414h20GlobeNewswire Inc.Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & ExpoNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/03/202413h00GlobeNewswire Inc.New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney DiseaseNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202421h25Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202412h26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202412h15GlobeNewswire Inc.Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202412h05GlobeNewswire Inc.Lexicon Announces Oversubscribed $250 Million Private Placement of Equity SecuritiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
11/03/202412h00GlobeNewswire Inc.Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDANASDAQ:LXRXLexicon Pharmaceuticals Inc
29/02/202422h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/02/202422h28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202422h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202422h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202422h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202422h16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202422h15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202422h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202422h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202422h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
12/02/202422h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LXRXLexicon Pharmaceuticals Inc
08/01/202413h00GlobeNewswire Inc.Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/12/202323h29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
29/12/202323h27Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:LXRXLexicon Pharmaceuticals Inc
29/12/202322h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LXRXLexicon Pharmaceuticals Inc
21/12/202322h15GlobeNewswire Inc.Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
30/11/202313h30GlobeNewswire Inc.Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP)NASDAQ:LXRXLexicon Pharmaceuticals Inc
22/11/202313h30GlobeNewswire Inc.Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:LXRX

Kürzlich von Ihnen besucht

NASDAQ
AMZN
Amazon.com
TG
DBK
Deutsche Bank
PM
XAUUSD
Gold vs US Dollar
NASDAQ
GOOGL
Alphabet
CCOM
US30
US 30
AMEX
SPY
SPDR S&P 500
TG
ALV
Allianz
TG
D7G
Nel ASA
DBI
SDXP
SDAX
DBI
DAX
DAX
TG
CBK
Commerzbank
NYSE
XOM
Exxon Mobil
TG
DTE
Deutsche Telekom
DBI
MDAX
MDAX
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten